Sofinnova Partners closes oversubscribed €82M Sofinnova MD Start IV fund

What happened

European life sciences venture capital firmSofinnova Partners has closed its fourth medtech fund, Sofinnova MD Start IV,at €82 million. Sofinnova plans to launch six to eight medtech companies through the fund over the next five years.

The strategy combines clinical insight, entrepreneurial talent and operational expertise to develop companies addressing unmet medical needs. Sofinnova also provides portfolio companies with access to its global network, drawing on more than a decade of experience building and scaling medtech companies. Sofinnova MD Start is one of the few strategies in Europe focused on creating medtech companies from the ground up.

Key facts

• Sofinnova also — provides: portfolio companies with access to its global network, drawing on more than a decade of experience building and scaling medtech companies